Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
MAL24066067NC
EMT is associated with decreased E-cadherin and increased N-cadherin expression, which was reversed by Sangju honey in oral carcinoma cells (85)
All treatments are customized based on a consultation with a medical provider
Eloralintide has active Phase 3 ENLIGHTEN trials, cagrilintide and CagriSema remain in Phase 3 development, and petrelintide completed the Phase 2 ZUPREME-1 study while Roche and Zealand prepare later-stage development
US$ 20.86
US$ 23.36
US$ 23.03
US$ 27.92
US$ 21.97
US$ 20.59
US$ 24.37
US$ 24.53
US$ 21.91
